Table 3.
Adverse Drug Reactionsa in Patients With MDR TB
| Adverse Drug Reactionsa | Total MDR TB (n = 129) | FQ-S MDR TB (n = 90) | FQ-R MDR TB (n = 39) | P |
|---|---|---|---|---|
| Gastrointestinal trouble | 92 (71.3) | 66 (73.3) | 26 (66.7) | .442 |
| Musculoskeletal painb | 46 (35.7) | 35 (38.9) | 11 (28.2) | .245 |
| Ototoxicityc | 42 (32.6) | 32 (35.6) | 10 (25.6) | .270 |
| Dermatologic abnormalities | 34 (26.4) | 24 (26.7) | 10 (25.6) | .903 |
| Endocrine abnormalitiesd | 29 (22.5) | 19 (21.1) | 10 (25.6) | .571 |
| Hepatotoxicity | 21 (16.3) | 15 (16.7) | 6 (15.4) | .856 |
| Peripheral neuropathy | 20 (15.5) | 7 (7.8) | 13 (33.3) | <.001 |
| Psychotic problems | 14 (10.9) | 11 (12.2) | 3 (7.7) | .550 |
| General weakness | 12 (9.3) | 8 (8.9) | 4 (10.3) | .753 |
| Hematologic abnormalitiese | 11 (8.5) | 5 (5.6) | 6 (15.4) | .087 |
| Eye toxicity | 9 (7.0) | 6 (6.7) | 3 (7.7) | 1.0 |
| Renal toxicity | 6 (4.7) | 6 (6.7) | 0 (0) | .178 |
| QT prolongation | 2 (1.6) | 2 (2.2) | 0 (0) | 1.0 |
| Othersf | 6 (4.7) | 6 (6.7) | 0 | .177 |
Data are presented as No. (%).
Abbreviations: FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-sensitive; MDR TB, multidrug-resistant tuberculosis.
aIncluded any drug adverse events, not only abnormality in medical test but also patients’ subjective symptoms.
bMusculoskeletal pain included myalgia and joint pain, based on patients’ subjective symptoms.
cTinnitus or hearing difficulty was based on subjective symptoms and auditory testing. Only newly developed symptoms after MDR TB treatment were included.
dEndocrine abnormalities were mainly hypothyroidism, and some hypoglycemia or hyperglycemia were also reported.
eDecrease of leukocyte, hemoglobin, or platelet count less than the lower normal limit.
fOther: fever, alopecia, anaphylactic shock.